Pre-order Enquiry
Download Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Chugai Pharmaceutical Co., Ltd. (4519) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Chugai Pharmaceutical Co., Ltd. (Chugai) is a subsidiary of Hoffmann-La Roche Ltd which focus on the manufacturing marketing, import and export of new pharmaceutical products. The company's product portfolio focuses on various therapeutic areas including cancer treatment; bone and joint diseases; renal diseases; transplant, immunology and infectious diseases and others. Chugai's products include Avastin, Herceptin, Rituxan, Xeloda, Neutrogin, Tarceva, and Kytril for cancer treatements; Evista, Actemra, Suvenyl, Alfarol, Edirol for in bone and joint diseases; and Epogin, Mircera, Oxarol for renal diseases. Under its transplant, immunological infectious diseases area it markets and distributes Pegasys, Copegus and CellCept. Other products offered by the company include Sigmart, Tamiflu and others. The company also markets its pharmaceutical products in overseas markets, such as the US, the UK, Germany, France, Taiwan, China and Korea. Chugai is headquartered at Chuo-ku in Tokyo, Japan.
Chugai Pharmaceutical Co., Ltd. Key Recent Developments
Nov 25, 2015: Chugai Pharmaceutical Announces Organizational and Personnel Changes
Oct 22, 2015: Chugai to Newly Construct an Antibody API Manufacturing Plant Capable of High-Mix Low-Volume Production in Preparation for the Consecutive Launch of Innovative Projects
Jul 23, 2015: Chugai Pharmaceutical Announces Relocation of the Tokyo First Branch
Jan 28, 2015: Chugai to Establish the Organization Specializing in Early Clinical Development
Jan 28, 2015: Chugai Pharmaceutical Announces Consolidated Financial Statements (non-audited) For Fiscal Year 2014
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Chugai Pharmaceutical Co., Ltd. (Chugai) is a subsidiary of Hoffmann-La Roche Ltd which focus on the manufacturing marketing, import and export of new pharmaceutical products. The company's product portfolio focuses on various therapeutic areas including cancer treatment; bone and joint diseases; renal diseases; transplant, immunology and infectious diseases and others. Chugai's products include Avastin, Herceptin, Rituxan, Xeloda, Neutrogin, Tarceva, and Kytril for cancer treatements; Evista, Actemra, Suvenyl, Alfarol, Edirol for in bone and joint diseases; and Epogin, Mircera, Oxarol for renal diseases. Under its transplant, immunological infectious diseases area it markets and distributes Pegasys, Copegus and CellCept. Other products offered by the company include Sigmart, Tamiflu and others. The company also markets its pharmaceutical products in overseas markets, such as the US, the UK, Germany, France, Taiwan, China and Korea. Chugai is headquartered at Chuo-ku in Tokyo, Japan.
Chugai Pharmaceutical Co., Ltd. Key Recent Developments
Nov 25, 2015: Chugai Pharmaceutical Announces Organizational and Personnel Changes
Oct 22, 2015: Chugai to Newly Construct an Antibody API Manufacturing Plant Capable of High-Mix Low-Volume Production in Preparation for the Consecutive Launch of Innovative Projects
Jul 23, 2015: Chugai Pharmaceutical Announces Relocation of the Tokyo First Branch
Jan 28, 2015: Chugai to Establish the Organization Specializing in Early Clinical Development
Jan 28, 2015: Chugai Pharmaceutical Announces Consolidated Financial Statements (non-audited) For Fiscal Year 2014
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Frequently Asked Questions
This market study covers the global and regional market with an
in-depth analysis of the
overall growth prospects...
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by
highlighting information on
different aspects including drivers, restraints...
